

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Dan Peer	POSITION TITLE Full Professor, Director, Laboratory of Precision NanoMedicine Chair, Tel Aviv University Cancer Biology Research Center.
-------------------------	---

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.)*

INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	MM/YY	FIELD OF STUDY
Tel Aviv University, Tel Aviv, Israel	B.S.	10/ 98	Biology
Tel Aviv University, Tel Aviv, Israel	M.S.	10/00	Biochemistry
Tel Aviv University, Tel Aviv, Israel	Ph.D.	09/04	Biophysics
University of Cambridge, Cambridge, UK (Cesar Milstein Lab)	Internship	06/00	Biochemistry
MIT (Robert Langer Lab)	Internship	10/03	Biomaterials
Harvard Medical School, Boston, MA, USA	Postdoctoral	08/08	Immunology

A. Positions

- 2019 - Vice Dean for Research, George S. Wise Faculty of Life Sciences, Tel Aviv University.
- 2017 - Founder and Managing Director, SPARK Tel Aviv, Center for Translational Medicine, Tel Aviv University.
- 2016 - Chair, Cancer Biology Research Center (CBRC), Tel Aviv University
- 2015 - Full Professor, and Director, Laboratory of Precision NanoMedicine, Tel Aviv University
- 2015 - Member, Translational Science Board, Kenneth Rainin Foundation.
- 2014 - Member, Israel Young Academy of Science.
- 2013 - 2016 Scientific Advisory Committee on IBD for the Leona M and Harry B. Helmsley Charitable Trust - projects operated by The Broad Institute of MIT and Harvard.
- 2012 - 2017. Director, Israel National Nanomedicine consortium.

Professional Service

- 2008 - Founder and Board Member, Leuko Biosciences, Boston, MA USA (mAb is developed by Genentech).
- 2010 - Editorial Board Member: Journal of Controlled Release
- 2010 - Founder and Board Member, Quiet Therapeutics, Boston, MA, USA.
- 2010 - Associate Editor: Journal of Biomedical Nanotechnology
- 2012 - Editorial Board Member: Biomedical Microdevices
- 2012 - Editorial Board Member: Cancer Letters
- 2013 - Associate Editor: BMC Biochemistry.
- 2014 - Editorial Advisory Board Member: Bioconjugate Chemistry
- 2014 - Scientific Advisory and Board Member (co-founder): SEPL Pharma
- 2015 - Associate Editor: Journal of Controlled Release.
- 2015 - Scientific Advisory and Board Member: ART Biosciences
- 2015 - Editorial Board Member: OpenNano
- 2016 - Scientific Advisory Member, Genentech, IBD Board, San Francisco, CA, USA
- 2016 - Scientific Board Member: International Longevity Alliance.
- 2017 - Scientific Advisory Board Member - Precision nanosystems Inc., Vancouver, Canada.
- 2017 - Scientific Advisory Board Member, Advanced Therapeutics
- 2017 - Chair, Scientific Advisory Board, SciCann Therapeutics, Toronto, Canada
- 2018 - Scientific Advisory Member, EuroPacific Medical, San Francisco, CA, USA
- 2018 - Scientific Advisory Member, New Phase Ltd., Israel
- 2018 - Editorial Board Member: Nanomaterials
- 2018 - Editorial Board Member: Biomaterials Research
- 2018 - Scientific Advisory Member, CX One Inc., Toronto, Canada
- 2018 - Founder and Board Member, NeoCure Pharma Inc., Boston, MA, USA.

Honors and Awards (Selected 5 out of 30)

2017: Nanos Award - World Leader Award for substantial contributions to the field of NanoMedicine, CLINAM Conference, Basel, Switzerland.

2015: 1st recipient of the UK-Israel Professorship (Oxford)

2014: Innovator Award, Untold News Award, NYC, NY, USA.

2014- 2016: President: Israel Chapter, Controlled Release Society.

2014 - 2018: Member and managing committee, Israel Young Academy of Science.

B. Contribution to Science

Overall > **130 peer-reviewed publications** and > **120 patent applications** (pending and granted) including strategies that were translated into clinical trials (one currently under registration (new drug in IBD) three under different clinical evaluations). Co-founded of four companies. More than 350 national and international seminars, keynote and plenary talks.

Selected papers are listed below:

1. **Peer D**, Zhu P, Carman CV, Lieberman J and Shimaoka M (2007). Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc. Natl. Acad.Sci. USA, 150, 4095-4100. * *The first activation depended silencing with RNAi in leukocytes*.
2. **Peer D***, Karp JM*, Hong S*, Farokhzad O, Margalit R, and Langer R (2007). Nanocarriers as emerging platforms for cancer therapy. Nature Nanotechnology 2,751-760. * *Highest cited paper in nanomedicine and cancer (cited > 6200 times)*.
3. **Peer D.**, Park EJ, Morishita Y, Carman CV, and Shimaoka M (2008). Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammation Target. Science. 319, 627-630. * The first example for in vivo drug discovery in immune cells using RNA interference. Highlight in Nature, Science, Nature Biotechnology, Nature Cell Biology, and more.
4. Kedmi R, Ben-Arie N, and **Peer D** (2010). The systemic toxicity of positively charged lipid-nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials.31, 6867-6.
5. Moyano D., Goldsmith M., Solfiell D., Landesman-Milo D., Miranda O., **Peer D.*** and Rotello VM* (2012). Hydrophobicity Dictates Immune response. Journal of American Chemical Society 134(9), 3965-3967. *Highlight in Nature 2013 ("The new gold standard")*.
6. Cohen K., Emmanuel R., Kisin-Finfer E., Shabat D., and **Peer D** (2014). Modulation of drug resistance in ovarian adenocarcinoma using chemotherapy entrapped in hyaluronan-grafted nanoparticle clusters. ACS Nano. 8 (3), 2183-2195
7. Cohen Z.R., Ramisetty S., Peshes-Yaloz N., Goldsmith M., Vol A., Zibly Z. and **Peer D** (2015). Localized RNAi Therapeutics of Chemo-Resistant Grade IV Glioma using Hyaluronan-Grafted Lipid-based Nanoparticles. ACS Nano. 9(2), 1581-1591.
8. Ramishetti S, Kedmi R, Goldsmith M, Leonard F, Speague AG, Godin B, Gozin M, Cullis P, Dykxhoorn DM, and **Peer D**. (2015). Systemic Gene Silencing in Primary T lymphocytes using Targeted Lipid Nanoparticles. ACS Nano 9(7):6706-16.
9. Weinstein S., Toker I.A., Emmanuel R., Ramishetti S., Hazan-Halevy I., Rosenblum D., Goldsmith M., Abraham A., Benjamini O., Bairey O., Raanani P., Nagler A., Lieberman J. and **Peer D** (2016). Harnessing RNAi based-Nanomedicines for Therapeutic Gene Silencing in B Cell Malignancies. Proc. Natl. Acad. Sci. USA 113 (1), E17-25.
10. Kedmi R. and **Peer D** (2016). Zooming in on selectins in Cancer. SCIENCE Translational Med. 8, 345fs11.
11. Mizrahy S, Hazan-Halevy I, Dammes N, Landesman-Milo D, and Peer D (2017). Current Progress in Non-viral RNAi-Based Delivery Strategies to Lymphocytes. Molecular Therapy 25(7):1491-1500.
12. Kedmi R., Viaga N. Ramishetti S, Goldsmith M, Rosenblum D, Dammes N, Hazan-Halevy I, Nahary L, Leviatan-Ben-Arye S, Harlev M, Behlke M, Benhar I, Lieberman J, and **Peer D** (2018). A modular platform for targeted RNAi therapeutics. Nature Nanotechnology. 13(3):214-219. A novel universal platform for RNAi therapeutics.
13. Rosenblum D., Joshi N., Tao W., Karp M.* , and **Peer D***. (2018). Progress and Challenges Towards Targeted Delivery of Cancer Therapeutics. Nature Communications Apr 12;9(1):1410. doi: 10.1038/s41467-018-03705-y.
14. Veiga N., Goldsmith M., Granot Y., Rosenblum D., Dammes N., Kedmi R., Ramishetti S., and **Peer D** (2018). Cell Specific Delivery of Modified mRNA Expressing Therapeutic Proteins to Leukocytes. Nature Communications 9(1):4493. doi: 10.1038/s41467-018-06936-1. The first, cell specific targeting of mRNA.